Oral Propanolol for Surgically Inaccessible Cavernous Malformations

• Status: Unknown status
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the role of propranolol as an alternative treatment for cavernous malformation in patients that may not be ideal candidates for surgery.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Virginia
• Treatments: Propranolol

Criteria

Inclusion Criteria:

1. Diagnosis of isolated or familial cavernous malformation syndrome:

• symptomatic cavernous malformation not amenable to surgical resection.

• familial cavernous malformation with seizure, other neurological symptom or surgically inaccessible lesion.

2. Written and informed consent obtained prior to study enrollment.

3. Subject is able and willing to return for outpatient visits.

4. Negative pregnancy test at time of enrollment for women and child-bearing potential.

Exclusion Criteria:

1. Age less than 1 year-old.

2. Propranolol allergy or allergy to other b-blockers.

3. Estimated life expectancy of less than 1 year.

4. History of severe anemia, cardiac dysfunction, or diabetes.

5. A psychiatric or substance abuse problem that may interfere with study compliance.

6. Pregnant and lactating women.